<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Spinocerebellar <z:hpo ids='HP_0001251'>ataxia</z:hpo> type 3 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e>) is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:hpo ids='HP_0002180'>neurodegenerative disease</z:hpo> caused by polyglutamine-expanded ataxin-3 </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we prepared a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> animal model by generating transgenic mice expressing disease-causing ataxin-3-Q79 </plain></SENT>
<SENT sid="2" pm="."><plain>Mutant ataxin-3-Q79 caused cerebellar malfunction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> transgenic mice by downregulating cerebellar <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions of proteins involved in synaptic transmission, signal transduction or regulating neuronal survival/differentiation </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> acetylation, which is controlled by <z:chebi fb="0" ids="15358">histone</z:chebi> acetyltransferase and <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase (HDAC), plays an important role in regulating transcriptional activity </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study, we tested the hypothesis that ataxin-3-Q79 causes cerebellar transcriptional downregulation by inducing <z:chebi fb="0" ids="15358">histone</z:chebi> hypoacetylation and that HDAC inhibitor <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> (SB) alleviates ataxic symptoms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> transgenic mice by reversing ataxin-3-Q79-induced <z:chebi fb="0" ids="15358">histone</z:chebi> hypoacetylation and transcriptional repression </plain></SENT>
<SENT sid="5" pm="."><plain>Compared to <z:mp ids='MP_0002169'>wild-type</z:mp> mice, H3 and H4 <z:chebi fb="0" ids="15358">histones</z:chebi> were hypoacetylated in the cerebellum of 6- to 8-month-old ataxin-3-Q79 transgenic mice, which displayed transcriptional downregulation and ataxic symptoms </plain></SENT>
<SENT sid="6" pm="."><plain>Daily intraperitoneal administration of SB significantly reversed ataxin-3-Q79-induced <z:chebi fb="0" ids="15358">histone</z:chebi> hypoacetylation and transcriptional downregulation in the cerebellum of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> transgenic mice </plain></SENT>
<SENT sid="7" pm="."><plain>SB treatment also delayed the <z:hpo ids='HP_0003674'>onset</z:hpo> of ataxic symptoms, ameliorated neurological phenotypes and improved the survival rate of ataxin-3-Q79 transgenic mice </plain></SENT>
<SENT sid="8" pm="."><plain>The present study provides the evidence that mutant ataxin-3-Q79 causes cerebellar transcriptional repression and ataxic symptoms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> transgenic mice by inducing hypoacetylation of <z:chebi fb="0" ids="15358">histones</z:chebi> H3 and H4 </plain></SENT>
<SENT sid="9" pm="."><plain>Our results suggest that <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> might be a promising therapeutic agent for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SCA3</z:e> </plain></SENT>
</text></document>